

1 COVID-19 Vaccine effectiveness among Healthcare Workers during the Omicron Period in the country 2 of Georgia, January – June 2022

3

4 Caleb L. Ward*¹, Madelyn Yiseth Rojas Castro*², Giorgi Chakhunashvili³, Nazibrola Chitaze³, Iris Finci⁴,
5 Richard Pebody⁴, Esther Kissling², Mark A. Katz⁴, Lia Sanodze³

6 1. Public Health Institute, Tbilisi, Georgia

7 2. Epiconcept, Paris, France

8 3. National Center for Disease Control and Public Health, Tbilisi, Georgia

9 4. World Health Organization Regional Office for Europe, Copenhagen, Denmark

10 *These two authors contributed equally to the manuscript

11 Abstract

12 Introduction

13 Understanding COVID-19 vaccine effectiveness (VE) in healthcare workers (HCWs) is critical to inform
14 vaccination policies. We measured COVID-19 VE against laboratory-confirmed symptomatic infection in
15 HCWs in the country of Georgia from January – June 2022, during a period of Omicron circulation.

16 Methods

17 We conducted a cohort study of HCWs in six hospitals in Georgia. HCWs were enrolled in early 2021.
18 Participants completed weekly symptom questionnaires. Symptomatic HCWs were tested by RT-PCR
19 and/or rapid antigen test (RAT). Participants were also routinely tested, at varying frequencies during
20 the study period, for SARS-CoV-2 by RT-PCR or RAT, regardless of symptoms. Serology was collected
21 quarterly throughout the study and tested by electrochemiluminescence immunoassay for SARS-CoV-2
22 antibodies. We estimated absolute and relative VE of a first booster dose compared to a primary vaccine
23 series as $(1 - \text{hazard ratio}) * 100$ using Cox proportional hazards models.

24 Results

25 Among 1253 HCWs, 141 (11%) received a primary vaccine series (PVS) and a first booster, 855 (68%)
26 received PVS only, and 248 (20%) were unvaccinated. Most boosters were BNT162b2 (Comirnaty
27 original monovalent) vaccine (90%) and BIBP-CorV vaccine (Sinopharm) (9%). Most PVS were BNT162b2
28 vaccine (68%) and BIBP-CorV vaccine (24%). Absolute VE for a first booster was 40% (95% Confidence
29 Interval (CI) -56 – 77) at 7– 29 days following vaccination, -9% (95% CI -104 – 42) at 30 – 59 days, and -
30 46% (95% CI -156 – 17) at ≥ 60 days. Relative VE of first booster dose compared to PVS was 58% (95% CI
31 1 – 82) at 7– 29 days following vaccination, 21% (95% CI -33 – 54) at 30 – 59 days, and -9% (95% CI -82 –
32 34) at ≥ 60 days.

33 Conclusion

34 In Georgia, first booster dose VE against symptomatic SARS-CoV-2 infection among HCWs was
35 moderately effective but waned very quickly during Omicron. Increased efforts to vaccinate priority
36 groups in Georgia, such as healthcare workers, prior to periods of anticipated high COVID-19 incidence
37 are essential.

38

39 Manuscript

40 **Introduction**

41 COVID-19 has caused high rates of illness and mortality in health care workers (HCWs).¹ HCWs are at
42 high risk of occupational exposure, and ensuring the safety and health of HCWs is critical for maintaining
43 functioning healthcare systems in pandemic and interpandemic periods.

44 COVID-19 vaccines are an important tool to reduce morbidity and mortality from SARS-CoV-2
45 infections.^{2,3} Reducing SARS-CoV-2 infections among HCWs can reduce absenteeism and also reduce the
46 possibility of onward transmission to vulnerable patients.^{4,5} While COVID-19 vaccine effectiveness (VE)
47 has been widely studied in high-income countries (HICs), few studies have evaluated COVID-19 booster
48 dose VE in middle-income countries (MICs) in Europe, where populations are different and a variety of
49 COVID-19 vaccines have been used in resource-limited settings.

50 Georgia is an upper-MIC in the South Caucasus with a population of 3.7 million people.⁶ Four two-dose
51 COVID-19 vaccines are currently approved for use among adults in the Republic of Georgia:
52 Oxford/AstraZeneca AZD1222, Pfizer/BioNTech BNT162b2, Sinopharm (Beijing) BBIBP-CorV, and Sinovac
53 (CoronaVac).⁷ HCWs were a priority group for vaccination after vaccines became available on 15 March
54 2021.⁸ As of May 2023, in Georgia, 34.6% of the population had received at least one dose, 31.6% had
55 received a PVS, and 6.7% had received a booster dose.⁹

56 In April 2021, we initiated a prospective cohort study of COVID-19 VE in HCWs in Georgia. VE estimates
57 against the Delta variant from this study have been previously published.¹⁰ Georgia was heavily affected
58 by the Omicron wave; daily new cases peaked in early February, 2022.¹¹ Here we evaluated COVID VE
59 during the early Omicron period using data from the same cohort (January 1 – June 1, 2022).

60

61 **Methods**

62 This cohort study has been described previously.^{10,12,13} Briefly, we enrolled HCWs from six hospitals in
63 Georgia. We collected information on socio-demographics, underlying conditions, hospital role, self-
64 assessed health status, prior SARS-CoV-2 infection, and COVID-19 history. Every participant provided a
65 blood sample for serology testing at the time of enrolment, and quarterly during the course of the study.
66 Serology samples were tested for anti-nucleocapsid antibody (Anti-N) and anti-spike antibody (Anti-S), as
67 previously described.¹⁰

68 Throughout the study timeline, participants completed a weekly symptom questionnaire, administered
69 by study personnel. Participants who reported any COVID-19 symptoms included in the Georgia Ministry
70 of Health (MoH) suspected COVID-19 definition (fever, cough, general weakness, fatigue, headache,
71 muscle aches, sore throat, runny nose, shortness of breath, lack of appetite, nausea, vomiting, diarrhea,
72 altered mental status, loss of taste, or loss of smell) provided a respiratory specimen, which was tested
73 for SARS-CoV-2 by PCR or RAT. During the entire study period, as part of the national COVID-19 response,
74 HCWs at all six hospitals were recommended to be tested every week for SARS-CoV-2 by RT-PCR or RAT,
75 but in practice testing was done inconsistently.

76 Participants who tested positive for SARS-CoV-2 by RT-PCR or RAT were administered a follow-up
77 questionnaire about their clinical course 30 days after the date of their positive test. Data on testing and
78 vaccination were confirmed using national databases.

79

80 *Vaccine effectiveness analysis*

81 As our primary analysis, we estimated first booster dose VE against PCR or RAT confirmed symptomatic
82 SARS-CoV-2 infection from January 1 to June 1, 2022, a period when >50% of weekly SARS-CoV-2
83 sequences in Georgia were Omicron variants BA.1 and BA.2, according to data from the Global Initiative
84 on Sharing All Influenza Data (GISAID)¹⁴(Figure 1). Our secondary analysis estimated the relative VE of
85 the first booster dose compared with primary vaccination series (PVS) among the population eligible for
86 receive a first booster dose. We measured VE at discrete time intervals since receipt of booster dose: 7
87 days – 29 days, 30 days – 59 days, and ≥ 60 days. We also estimated VE specifically for BNT162b2 and
88 against medically attended COVID-19.

89 Figure 1. SARS-CoV-2 variant distribution in Georgia, data from GISAID¹⁴

90

91 Participants were considered to be fully vaccinated with PVS ≥ 14 days after their second COVID-19
92 vaccine dose, and for booster doses ≥ 7 days after the booster vaccination. In order to be consistent with
93 Georgia MoH guidelines, participants were considered to be eligible for a first booster dose ≥ 150 days
94 after PVS. If participants reported a previous PCR-confirmed SARS-CoV-2 infection they were considered
95 as having a prior infection. In addition, unvaccinated participants and participants who had not received
96 any inactivated vaccines were seropositive for Anti-Nucleocapsid antibodies at the beginning of the
97 analysis period were considered to have previous infection. We could not use serology test results to

98 determine prior infection for participants who were previously vaccinated with an inactivated vaccine
99 (BBIBP-CorV or CoronaVac), as these vaccines routinely generate anti-nucleocapsid antibodies.

100 *Statistical model*

101 We estimated VE as $(1 - \text{hazard ratio}) * 100$. Hazard ratios comparing vaccinated and referenced groups
102 were estimated using Cox proportional hazards models with vaccination as a time-varying exposure.
103 Vaccination status of some individuals changed over time from unvaccinated to PVS, and from PVS to
104 boosted. Person-time from participants with either only one dose or more than three doses were
105 excluded. Calendar time was used as the underlying time in the Cox regression. We calculated
106 unadjusted and adjusted VE including the hospital site as strata to account for site-specific variation. We
107 adjusted the multivariable regression model using a priori fixed covariates: age groups, sex, any
108 underlying chronic condition (yes/no), self-assessed health status, household size, daily face-to-face
109 patient contact, previous SARS-CoV-2 infection (confirmed by RT-PCR, RAT, or serology), smoking status.

110 Participants contributed person-time from the start of the study period (1 January 2022), or from 90
111 days after a prior SARS-CoV-2 infection (whichever was later), until whichever of the following endpoints
112 came first: 1) the day of the first SARS-CoV-2 symptomatic infection 2) the day of receipt of a second
113 booster vaccine dose, or 3) the day of the last weekly questionnaire before complete loss to follow-up,
114 or withdrawal from the study.

115 This study was approved by Georgia NCDC and WHO Research Ethics Committees. All participants
116 provided written informed consent.

117

118 **Results**

119 On January 1, 2022, there were 1592 HCWs enrolled in the study; 1253 were included in this analysis
120 (Figure 2). Of those included in the analysis, the median age was 41 (Interquartile range: 30-53), 1058
121 (84%) were female, and 316 (25%) reported having at least one chronic condition. Most HCWs were
122 nurses or midwives (39%) and medical doctors (21%). The majority of HCWs (64%) had evidence of prior
123 SARS-CoV-2 infection at the beginning of the analysis period (Table 1).

124 Figure 2. Flowchart showing enrolment of healthcare workers in COVID-19 vaccine effectiveness study,
125 Georgia, 2021-2022.

126

Table 1. Demographic, occupational, and clinical characteristics among study participants by vaccination status at the beginning of the study period on 1 January 2022, Georgia (N= 1253).

	Missin g	All Participant s	Unvaccinate d	Vaccinated with Primary Series	First Booste r dose
Age	0	n= 1253	n= 248	n= 855	n= 141
Median (IQR)		41 (30-53)	39 (28-52)	40 (30-52)	49 (37-60)
Age group	0	n= 1253	n= 248	n= 855	n= 141
<20, n(%)		13 (1)	1 (<1)	12 (1)	0 (0)
20-29, n(%)		281 (22)	68 (27)	193 (23)	16 (11)
30-39, n(%)		275 (22)	57 (23)	192 (22)	26 (18)
40-49, n(%)		268 (21)	48 (19)	189 (22)	30 (21)
50-59, n(%)		262 (21)	51 (21)	175 (20)	32 (23)
60+, n(%)		154 (12)	23 (9)	94 (11)	37 (26)
Sex	0	n= 1253	n= 248	n= 855	n= 141
F, n(%)		1058 (84)	206 (83)	731 (85)	114 (81)
M, n(%)		195 (16)	42 (17)	124 (15)	27 (19)
Hospital	0	n= 1253	n= 248	n= 855	n= 141
Academician Hospital, n(%)		229 (18)	27 (11)	154 (18)	46 (33)
Batumi Republican Hospital, n(%)		238 (19)	31 (12)	174 (20)	28 (20)
Bochoroshvili Hospital, n(%)		137 (11)	31 (12)	96 (11)	8 (6)
Bokeria Hospital, n(%)		249 (20)	57 (23)	166 (19)	26 (18)
Caucasus Medical Centre, n(%)		236 (19)	57 (23)	162 (19)	17 (12)
Infectious Disease Hospital, n(%)		164 (13)	45 (18)	103 (12)	16 (11)
Occupation/Role in hospital	0	n= 1253	n= 248	n= 855	n= 141
Nurse or Midwife, n(%)		487 (39)	103 (42)	357 (42)	24 (17)
Medical Doctor, n(%)		257 (21)	20 (8)	160 (19)	76 (54)
Other, n(%)		509 (41)	125 (50)	338 (40)	41 (29)
Household size	0	n= 1253	n= 248	n= 855	n= 141
1-3, n(%)		574 (46)	125 (50)	368 (43)	77 (55)
4-5, n(%)		494 (39)	93 (38)	355 (42)	41 (29)
6+, n(%)		185 (15)	30 (12)	132 (15)	23 (16)
Number of chronic conditions	0	n= 1253	n= 248	n= 855	n= 141
0, n(%)		937 (75)	184 (74)	659 (77)	86 (61)

1, n(%)		248 (20)	53 (21)	154 (18)	40 (28)
2+, n(%)		68 (5)	11 (4)	42 (5)	15 (11)
BMI	0	n= 1253	n= 248	n= 855	n= 141
Underweight or normal, n(%)		570 (45)	115 (46)	393 (46)	56 (40)
Overweight, n(%)		386 (31)	70 (28)	262 (31)	53 (38)
Obese, n(%)		297 (24)	63 (25)	200 (23)	32 (23)
Smoking status	0	n= 1253	n= 248	n= 855	n= 141
Currently smokes, n(%)		304 (24)	57 (23)	204 (24)	38 (27)
Never smokes, n(%)		835 (67)	169 (68)	582 (68)	80 (57)
Previously smokes, n(%)		114 (9)	22 (9)	69 (8)	23 (16)
Self-assessed health status	0	n= 1253	n= 248	n= 855	n= 141
Excellent, n(%)		101 (8)	22 (9)	65 (8)	14 (10)
Very good, n(%)		201 (16)	39 (16)	136 (16)	25 (18)
Good, n(%)		420 (34)	84 (34)	291 (34)	40 (28)
Fair, n(%)		513 (41)	94 (38)	356 (42)	60 (43)
Poor, n(%)		18 (1)	9 (4)	7 (<1)	2 (1)
Hands on care	0	n= 1253	n= 248	n= 855	n= 141
No, n(%)		581 (46)	134 (54)	385 (45)	58 (41)
Yes, n(%)		672 (54)	114 (46)	470 (55)	83 (59)
Face-to-face patient contact	0	n= 1253	n= 248	n= 855	n= 141
No, n(%)		266 (21)	67 (27)	172 (20)	24 (17)
Yes, n(%)		987 (79)	181 (73)	683 (80)	117 (83)
Previous COVID-19 infection before the start of the analysis period (confirmed by RT-PCR, Rapid antigen test, or serology)	0	n= 1253	n= 248	n= 855	n= 141
No, n(%)		171 (14)	35 (14)	113 (13)	21 (15)
Yes, n(%)		1082 (86)	213 (86)	742 (87)	120 (85)
Delay between PVS and start of person-time contribution	257	n= 996	n= 0	n= 855	n= 141
Median (IQR)		137 (115.8-190)	–	132 (112-159)	235 (187-268)
Delay between first booster dose and start of person-time contribution	1112	n= 141	n= 0	n= 0	n= 141

Median (IQR)		31 (14-50)	–	–	31 (14-50)
PVS product at start of person-time contribution	5	n= 1248	n= 248	n= 850	n= 141
AstraZeneca, n(%)		23 (2)	0 (0)	12 (1)	11 (8)
BNT162b, n(%)		678 (54)	0 (0)	581 (68)	97 (69)
Sinopharm, n(%)		224 (18)	0 (0)	204 (24)	20 (14)
Sinovac, n(%)		52 (4)	0 (0)	42 (5)	10 (7)
Unvaccinated, n(%)		248 (20)	248 (100)	0 (0)	0 (0)
First booster dose product at start of person-time contribution	1112	n= 141	n= 0	n= 0	n= 141
BNT162b, n(%)		130 (92)	0 (0)	0 (0)	130 (92)
Sinopharm, n(%)		11 (8)	0 (0)	0 (0)	11 (8)

127

128 At the beginning of the study period, 855 (68%) had received PVS, 141 (11%) had received a first booster
 129 dose, and 248 (20%) remained unvaccinated. Most boosters were BNT162b2 vaccine (92%) and BIBP-
 130 CorV vaccine (8%), and most PVS were BNT162b2 vaccine (68%) and BIBP-CorV vaccine (24%) (Table 1).

131 During the analysis period, there were a total of 372 PCR or RAT-confirmed SARS-CoV-2 symptomatic
 132 infections before exclusions; 63 symptomatic infections among unvaccinated participants, 264
 133 symptomatic infections among PVS, and 45 symptomatic infections among those who received a first
 134 booster dose (Figure 3). Overall, 267 (68%) of infected participants completed the clinical course at 30
 135 days questionnaire. In total, 126 (47%) of infected participants sought medical care, and 8 (3%) were
 136 hospitalized.

137 Figure 3. Number of symptomatic SARS-CoV-2 positive healthcare workers by vaccination status and
 138 time since vaccination, January - June 2022

139 Absolute booster dose VE against symptomatic SARS-CoV-2 infection was 40% (95% CI -56 – 77) in the
 140 7–29 days following receipt of the first booster dose, -9% (95% CI -104 – 42) for 30 – 59 days following
 141 receipt of the first booster dose, and -46% (95% CI -156 – 17) for ≥ 60 days following receipt of the first
 142 booster dose (Table 2, Figure 4).

143 Figure 4. Absolute and relative COVID-19 vaccine effectiveness against symptomatic infection and
 144 medically attended HCWs across different time periods, for Omicron-predominant period, Georgia,
 145 2022.

Table 2. Absolute and Relative Vaccine Effectiveness of primary vaccination series (PVS) vs first booster dose in protecting against symptomatic PCR and/or RAT-confirmed SARS-CoV-2 infection, overall and for BNT162b2 only, and against medically attended COVID-19, for the Omicron-predominant period only, Georgia, January 1 – June 1, 2022.

	N participants	Total person-time (days)	PCR-confirmed symptomatic COVID-19 infection	RAT-confirmed symptomatic COVID-19 infection	All symptomatic COVID-19 infections	Unadjusted VE or rVE	(95% CI)	Absolute VE or Relative VE*	(95%CI)
Absolute vaccine effectiveness (all vaccines)									
Time since first booster vs. unvaccinated	435								
Unvaccinated [ref]	248	23806	38	25	63				
7d - 29d from first booster dose	120	2178	4	2	6	34.0	(-63; 73.3)	40.4	(-55.9; 77.2)
30d-59d from booster dose	150	3655	13	2	15	-35.1	(-143; 24.9)	-8.6	(-103.9; 42.1)
≥60d from first booster dose	152	11497	11	7	18	-53.8	(-158.7; 8.6)	-45.9	(-155.7; 16.7)
Relative vaccine effectiveness (all vaccines)									
Time since first booster doses vs. PVS (All vaccines)	1070								
150d+ from PVS [ref]	698	51752	107	41	148				
7d - 29d from first booster dose	120	2178	4	2	6	58.6	(4.6; 82.1)	57.5	(0.5; 81.9)
30d-59d from first booster dose	150	3655	13	2	15	18	(-39.6; 51.8)	21.4	(-32.9; 53.6)
≥60d from first booster dose	152	11497	11	7	18	-2.6	(-68.8; 37.6)	-9.4	(-82; 34.3)
Relative vaccine effectiveness of BNT162b2									
Time since first booster doses vs. PVS (BNT162b2)	537								
150d+ from PVS [ref]	451	32530	70	30	100				

7d - 29d from first booster dose	66	1255	1	1	2	77.9	(6.6; 94.8)	77.4	(3.4; 94.7)
30d-59d from first booster dose	89	2114	6	2	8	26.2	(-51.2; 63.9)	26.4	(-47.2; 63.2)
≥60d from first booster dose	100	7455	10	5	15	-3.7	(-78.8; 39.9)	-15.6	(-103.1; 34.2)
Absolute vaccine effectiveness against Medically attended COVID-19 (all vaccines)									
Time since first booster dose vs. unvaccinated	435								
Unvaccinated [ref]	248	23806	24	12	36				
7d - 29d from first booster dose	120	2178	1	2	3	42.4	(-109.6; 84.2)	45.3	(-120.8; 86.4)
30d-59d from first booster dose	150	3655	5	0	5	6.3	(-145.4; 64.2)	29.1	(-71; 70.6)
≥60d from first booster dose	152	11497	3	2	5	15.2	(-110.3; 65.8)	21.2	(-103.9; 69.5)
Absolute vaccine effectiveness against Medically attended COVID-19 (all vaccines)									
Time since first booster doses vs. PVS	822								
150d+ from PVS [ref]	698	51752	51	22	73				
7d - 29d from first booster dose	120	2178	1	2	3	58.2	(-40.3; 87.5)	-	-
30d-60d from first booster dose	150	3655	5	0	5	40.8	(-47.3; 76.2)	32.8	(-66.5; 72.8)
≥60d from first booster dose	152	11497	3	2	5	37.2	(-56.4; 74.8)	26.6	(-90.1; 71.7)

*VE estimates were adjusted for hospital site (strata) age groups, sex, any underlying chronic condition, self-assessed health status, household size, daily face-to-face patient contact, previous COVID-19 infection, and smoking status.

146 Relative VE of a booster dose compared to PVS against symptomatic infection was 58% (95% CI 1 – 82)
147 for 7 days – 29 days from first booster dose receipt, 21% (95% CI -33 – 54) for 30 days – 59 days from
148 first booster dose receipt, and -9% (95%CI -82 – 34) for ≥ 60 days from first booster dose receipt (Table 2,
149 Figure 4).

150 Relative VE for a first booster dose of BNT162b2 vaccine compared to only a PVS (≥ 150 d) of BNT162b2
151 vaccine against symptomatic infection was 77% (95%CI 3 – 94) for 7 days – 29 days from the first
152 booster dose receipt, 26% (95% CI -47 – 63) for 30 days – 59 days from the first booster dose receipt,
153 and -16% (95%CI -103 – 34) for ≥ 60 days from the first booster dose receipt (Table 2, Figure 4). VE for
154 other booster vaccines could not be calculated due to small sample size.

155 Absolute VE of a first booster dose against medically attended infection was 45% (95% CI -121 – 86) for 7
156 days – 29 days from the first booster dose receipt, 29% (95% CI -71 – 71) for 30 days – 59 days from the
157 first booster dose receipt, and 21% (95% CI -104 – 70) for ≥ 60 days from booster dose receipt VE (Table
158 2, Figure 4).

159 Relative VE for a booster dose compared to PVS against medically attended infection was 45% (95% CI -
160 121 – 87) for 7d – 29d from booster dose receipt, 33% (95% CI -67 – 73), for 30d – 59 days from the first
161 booster dose receipt, and 27% (95%CI -90 – 72). for ≥ 60 d from the first booster dose receipt (Table 2,
162 Figure 4).

163 Discussion

164 During Omicron circulation in early 2022 in Georgia, we found moderate COVID-19 absolute VE ($\geq 40\%$)
165 of the first booster dose against both symptomatic and medically attended infection that rapidly waned
166 after 29 days in a cohort of HCWs with a high rate of previous infection. Relative VE against symptomatic
167 infection was slightly higher (58%) for a first booster dose compared to PVS, but relative VE also quickly
168 waned after 29 days since vaccination.

169 Our finding of moderate VE against symptomatic infection that rapidly waned during Omicron is similar
170 to findings from other studies showing moderate VE against Omicron that decreased over time. A
171 systematic review of VE against symptomatic infection during the Omicron period found pooled
172 estimates of VE after any PVS and any booster dose waned over time. VE after 1 month from PVS was
173 53%, after 6 months was 14%, and decreased to 9% after 9 months since PVS. VE after 1 month since
174 receiving any booster dose was 60%, after 6 months VE was 23%, and after 9 months VE was 13%.¹⁵ A
175 multi-country study in Europe of COVID-19 VE against symptomatic infection during Omicron (Dec 2021

176 – June 2022) also found significant waning in protection. All-product PVS VE was 60% <90 days since
177 vaccination and 29% ≥ 180 after vaccination. All-product first booster VE was 56% <90 days since
178 vaccination and 3% ≥ 180 after vaccination.¹⁶

179 A study of COVID-19 VE against symptomatic infection during Omicron from England (November 2021 to
180 January 2022) showed that booster dose BNT162b2 VE against symptomatic infection was 67% following
181 1 week of booster dose receipt and then receded to 46% after 10 weeks.¹⁷ Another study in England of
182 COVID-19 VE against symptomatic infection during BA.1 and BA.2 (January – March, 2022) found VE of a
183 first booster dose against symptomatic infection with BA.1 or BA.2 1 week after vaccination was 71%
184 and 74%, respectively. VE against the same outcome >15 weeks after vaccination for BA.1 and BA.2 was
185 37% and 44%, respectively.¹⁸ VE of PVS against symptomatic infection from <2 weeks since vaccination
186 for BA.1 and BA.2 was 63% and 64%, respectively. VE of PVS against symptomatic infection from 25+
187 weeks since vaccination for BA.1 and BA.2 was 15% and 28%, respectively.¹⁸ Another study of COVID-19
188 VE against symptomatic infection during Omicron from Canada (December 2021) showed that VE of PVS
189 against symptomatic infection was 36% from 7-59 days since vaccination and 15% from 120-179 days
190 since vaccination.¹⁹

191 The above studies indicate overall a slower decline in VE compared to our study, which indicates a rapid
192 decline. Our HCW setting differs from these studies, all of which are in the general population. HCW are
193 likely to have higher exposure levels to SARS-CoV-2 than the general population.²⁰ Within our study
194 population, the epidemic curve was extremely steep (Figure 3); 95% of HCWs infected during the study
195 period had a symptomatic SARS-CoV-2 infection between 1 January and end of February. This comprises
196 28% of the total study population. This force of infection, and the context of COVID-19 vaccines being at
197 least partially leaky vaccine,^{21,22} meaning that protection may be affected by number of exposures, may
198 explain at least in part the more rapid decline in VE observed in our study.

199 The higher point estimates for relative VE compared to absolute VE suggest that the risk of symptomatic
200 infection among individuals who completed their primary series more than 150 days ago was higher
201 than the risk of symptomatic infection among the unvaccinated. We would expect that the risk of
202 symptomatic infection among those vaccinated with primary series more than 150 days ago would be
203 the same or if anything slightly lower than the unvaccinated, in case of residual protection. This
204 difference may reflect differences between unvaccinated HCWs and those vaccinated more than 150
205 days ago in terms of virus exposure or variability in seroprotection related to previous infection.

206 However, as confidence intervals overlap between estimates, there is uncertainty in this difference, and
207 it may be due to random error.

208 While we found that moderate VE against symptomatic infection rapidly waned, we were not able to
209 evaluate VE against more severe endpoints than medically attended COVID-19. Studies have found that
210 COVID-19 vaccine continues to be effective in preventing severe disease. A multi-country study in
211 Europe during a period of Omicron-predominant circulation (December 2021 – July 2022) found that
212 COVID-19 VE against hospitalization was 43% for PVS and 59% for a first booster dose for ≥ 150 days
213 between the last PVS and symptom onset or last PVS and booster dose with 85% VE if illness onset was
214 14-59 days after booster receipt.²³ A study in the Netherlands from October – December 2023 looking
215 at VE in those aged ≥ 60 during found VE against hospitalization was 71%²⁴

216 Our study had several strengths. We used PCR-confirmed infection and serology to determine
217 participants with prior infections. We used both PCR testing and rapid antigen tests to identify infections
218 more completely among study participants. We were able to adjust for different confounders in our VE
219 analysis. We were also able to evaluate VE against the more severe endpoint of medically attended
220 infections.

221 Our study also had limitations. Our study was underpowered to detect the true effect in some sub-group
222 analyses, particularly those with a low number of events. Therefore, results of sub-group analyses
223 should be interpreted cautiously. Our study was not powered to assess VE against more severe
224 outcomes such as hospitalization, ICU admission, or death. Our sample size was low for estimating
225 certain time periods of VE and medically attended VE, which resulted in wide CIs. We were unable to
226 stratify VE by prior infection status or estimate vaccine products other than BNT162b2 due to the small
227 sample size. HCWs in our study enrolled voluntarily, which may have caused selection bias. However, we
228 managed to enroll 40% of HCWs in the 6 study hospitals.¹⁰

229 Overall, we found that COVID-19 booster doses were moderately effective at preventing symptomatic
230 infection in hospital based HCWs in Georgia but VE rapidly waned. This study was conducted in the
231 context of high previous infection and a high force of infection. These results suggest that timing COVID-
232 19 vaccination campaigns prior to periods of anticipated high SARS-CoV-2 incidence, if practical, could
233 be important to reduce COVID-19 infections. The moderate but waning VE in this study against
234 symptomatic and medically attended infection combined with the more durable COVID-19 VE against

235 severe outcomes described in other studies, underscore the need for broader efforts in Georgia to
236 increase vaccine coverage among priority groups such as HCWs.

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259 **Acknowledgements:** We are grateful to the study team at the Georgia National Centers for Disease
260 Control and at all the participating study hospitals. In addition, we would like to thank the following
261 colleagues: Tamuna Zardiashvili, C Jason McKnight, and Irina Begiashvili (WHO/Georgia), Pernille
262 Jorgensen and Diogo Simao Lemos (WHO/Europe), Lindsey Duca (US CDC), Marta Valenciano and Alain
263 Moren (Epiconcept). This study has been conducted within the framework of the WHO Strategic
264 Preparedness and Response plan and WHO/European Regional Office Response for COVID-19.

265 References


266

- 267 1. Bandyopadhyay S, Baticulon RE, Kadhum M, et al. Infection and mortality of healthcare workers
268 worldwide from COVID-19: a systematic review. *BMJ Glob Health*. 2020;5(12):e003097.
269 doi:10.1136/bmjgh-2020-003097
- 270 2. Shoukat A, Vilches TN, Moghadas SM, et al. Lives saved and hospitalizations averted by COVID-19
271 vaccination in New York City: a modeling study. *Lancet Reg Health - Am*. 2022;5:100085.
272 doi:10.1016/j.lana.2021.100085
- 273 3. Vilches TN, Sah P, Moghadas SM, et al. COVID-19 hospitalizations and deaths averted under an
274 accelerated vaccination program in northeastern and southern regions of the USA. *Lancet Reg Health -*
275 *Am*. 2022;6:100147. doi:10.1016/j.lana.2021.100147
- 276 4. Maltezou HC, Panagopoulos P, Sourri F, et al. COVID-19 vaccination significantly reduces morbidity
277 and absenteeism among healthcare personnel: A prospective multicenter study. *Vaccine*.
278 2021;39(48):7021-7027. doi:10.1016/j.vaccine.2021.10.054
- 279 5. Regev-Yochay G, Amit S, Bergwerk M, et al. Decreased infectivity following BNT162b2 vaccination: A
280 prospective cohort study in Israel. *Lancet Reg Health – Eur*. 2021;7. doi:10.1016/j.lanepe.2021.100150
- 281 6. Georgia Population (2022) - Worldometer. Accessed December 23, 2022.
282 <https://www.worldometers.info/world-population/georgia-population/>
- 283 7. Georgia – COVID19 Vaccine Tracker. Accessed October 20, 2021.
284 <https://covid19.trackvaccines.org/country/georgia/>
- 285 8. Lucaccioni H, Chakhunashvili G, McKnight CJ, et al. Sociodemographic and Occupational Factors
286 Associated with Low Early Uptake of COVID-19 Vaccine in Hospital-Based Healthcare Workers, Georgia,
287 March-July 2021. *Vaccines*. 2022;10(8):1197. doi:10.3390/vaccines10081197
- 288 9. WHO/Europe Covid-19 vaccine programme monitor. Accessed May 9, 2024.
289 https://worldhealthorg.shinyapps.io/EURO_COVID-19_vaccine_monitor/
- 290 10. Katz MA, Castro MYR, Chakhunashvili G, et al. Primary Series COVID-19 Vaccine Effectiveness among
291 Health Care Workers in the Country of Georgia, March–December 2021. Published online October 4,
292 2023. doi:10.20944/preprints202310.0224.v1
- 293 11. Trend in COVID-19 cases, Georgia | WHO COVID-19 dashboard. Accessed July 4, 2024.
294 <https://data.who.int/dashboards/covid19/cases>
- 295 12. World Health Organization. Regional Office for Europe. Cohort Study to Measure COVID-19 Vaccine
296 Effectiveness among Healthcare Workers in the WHO European Region: Guidance Document. Published
297 online 2021. Accessed April 15, 2024. [https://www.who.int/publications-detail-redirect/WHO-EURO-](https://www.who.int/publications-detail-redirect/WHO-EURO-2021-2141-41896-57484)
298 [2021-2141-41896-57484](https://www.who.int/publications-detail-redirect/WHO-EURO-2021-2141-41896-57484)

- 299 13. World Health Organization. Unity Studies: Early Investigation Protocols. Accessed April 15, 2024.
300 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early->
301 investigations
- 302 14. Khare S, Gurry C, Freitas L, et al. GISAID's Role in Pandemic Response. *China CDC Wkly.*
303 2021;3(49):1049-1051. doi:10.46234/ccdcw2021.255
- 304 15. Menegale F, Manica M, Zardini A, et al. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced
305 Immunity: A Systematic Review and Meta-analysis. *JAMA Netw Open.* 2023;6(5):e2310650.
306 doi:10.1001/jamanetworkopen.2023.10650
- 307 16. Delaunay CL, Martínez-Baz I, Sève N, et al. COVID-19 vaccine effectiveness against symptomatic
308 infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary
309 care study, Europe, December 2021 to June 2022. *Eurosurveillance.* 2024;29(13):2300403.
310 doi:10.2807/1560-7917.ES.2024.29.13.2300403
- 311 17. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron
312 (B.1.1.529) Variant. *N Engl J Med.* 2022;386(16):1532-1546. doi:10.1056/NEJMoa2119451
- 313 18. Kirsebom FCM, Andrews N, Stowe J, et al. COVID-19 vaccine effectiveness against the omicron
314 (BA.2) variant in England. *Lancet Infect Dis.* 2022;22(7):931-933. doi:10.1016/S1473-3099(22)00309-7
- 315 19. Buchan SA, Chung H, Brown KA, et al. Estimated Effectiveness of COVID-19 Vaccines Against
316 Omicron or Delta Symptomatic Infection and Severe Outcomes. *JAMA Netw Open.* 2022;5(9):e2232760.
317 doi:10.1001/jamanetworkopen.2022.32760
- 318 20. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and
319 the general community: a prospective cohort study. *Lancet Public Health.* 2020;5(9):e475-e483.
320 doi:10.1016/S2468-2667(20)30164-X
- 321 21. Lind ML, Dorion M, Houde AJ, et al. Evidence of leaky protection following COVID-19 vaccination
322 and SARS-CoV-2 infection in an incarcerated population. *Nat Commun.* 2023;14(1):5055.
323 doi:10.1038/s41467-023-40750-8
- 324 22. Halloran, M. E., Longini, I. M. & Struchiner, C. J. (Eds) *In Design and Analysis of Vaccine Studies.* 131–
325 136 (Springer New York, 2010).
- 326 23. Rose AM, Nicolay N, Martín VS, et al. Vaccine effectiveness against COVID-19 hospitalisation in
327 adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE
328 networks, Europe, 2021 to 2022. *Eurosurveillance.* 2023;28(47):2300187. doi:10.2807/1560-
329 7917.ES.2023.28.47.2300187
- 330 24. Werkhoven CH van, Valk AW, Smagge B, et al. Early COVID-19 vaccine effectiveness of XBB.1.5
331 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5
332 December 2023. *Eurosurveillance.* 2024;29(1):2300703. doi:10.2807/1560-7917.ES.2024.29.1.2300703
- 333

Number of samples sequenced

Other Delta (B.1.617.2) Omicron (BA.1) Omicron (BA.2) Omicron (BA.4)



Data downloaded from GISAID on 09/01/2024

Figure 1. GISAID




Figure 2. Flowchart





Figure 3. EpiCurve



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.19.24314033>; this version posted September 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure 4. Forest Plot